Compare TSEM & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | IQV |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | Israel | United States |
| Employees | N/A | 93000 |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 28.6B |
| IPO Year | 1996 | 2013 |
| Metric | TSEM | IQV |
|---|---|---|
| Price | $245.27 | $172.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $161.75 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $19.21 | $6.77 |
| Revenue Next Year | $26.62 | $5.89 |
| P/E Ratio | ★ $66.16 | $105.80 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $37.48 | $134.65 |
| 52 Week High | $283.46 | $247.05 |
| Indicator | TSEM | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 51.98 |
| Support Level | $111.97 | $159.08 |
| Resistance Level | N/A | $172.80 |
| Average True Range (ATR) | 17.60 | 6.78 |
| MACD | 3.64 | 0.50 |
| Stochastic Oscillator | 58.81 | 62.89 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs) based on the design specifications of customers. The company's line of integrated circuits is incorporated into markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.